NZ744649A - Compositions and methods for the treatment of hemoglobinopathies - Google Patents
Compositions and methods for the treatment of hemoglobinopathiesInfo
- Publication number
- NZ744649A NZ744649A NZ744649A NZ74464916A NZ744649A NZ 744649 A NZ744649 A NZ 744649A NZ 744649 A NZ744649 A NZ 744649A NZ 74464916 A NZ74464916 A NZ 74464916A NZ 744649 A NZ744649 A NZ 744649A
- Authority
- NZ
- New Zealand
- Prior art keywords
- hemoglobinopathies
- compositions
- treatment
- methods
- cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Mycology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides gRNA molecules targeting BCL11A, compositions, cells, and methods of preparing said gRNA molecules and cells for the treatment of hemoglobinopathies. In a particular embodiment, the gRNA molecule comprises a tracr and crRNA, wherein the crRNA comprises a targeting domain comprising UCAGUGAGAUGAGAUAUCAA (SEQ ID NO: 185).
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ783532A NZ783532B2 (en) | 2016-12-26 | Compositions and methods for the treatment of hemoglobinopathies | |
| NZ783531A NZ783531B2 (en) | 2016-12-26 | Compositions and methods for the treatment of hemoglobinopathies | |
| NZ783534A NZ783534A (en) | 2015-12-28 | 2016-12-26 | Compositions and methods for the treatment of hemoglobinopathies |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562271968P | 2015-12-28 | 2015-12-28 | |
| US201662347484P | 2016-06-08 | 2016-06-08 | |
| PCT/IB2016/058007 WO2017115268A1 (en) | 2015-12-28 | 2016-12-26 | Compositions and methods for the treatment of hemoglobinopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ744649A true NZ744649A (en) | 2025-09-26 |
Family
ID=57822008
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ744649A NZ744649A (en) | 2015-12-28 | 2016-12-26 | Compositions and methods for the treatment of hemoglobinopathies |
| NZ783534A NZ783534A (en) | 2015-12-28 | 2016-12-26 | Compositions and methods for the treatment of hemoglobinopathies |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ783534A NZ783534A (en) | 2015-12-28 | 2016-12-26 | Compositions and methods for the treatment of hemoglobinopathies |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20190010495A1 (en) |
| EP (2) | EP3397767A1 (en) |
| JP (4) | JP2019500043A (en) |
| KR (2) | KR20250141840A (en) |
| CN (1) | CN108779462A (en) |
| AU (4) | AU2016381313B2 (en) |
| CA (1) | CA3009727A1 (en) |
| EA (1) | EA201891532A1 (en) |
| HK (1) | HK1258205A1 (en) |
| IL (2) | IL260257B2 (en) |
| MX (2) | MX2018007987A (en) |
| MY (1) | MY192848A (en) |
| NZ (2) | NZ744649A (en) |
| PH (1) | PH12018501378A1 (en) |
| SG (1) | SG11201805217XA (en) |
| WO (1) | WO2017115268A1 (en) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| CN105939767B (en) | 2014-01-08 | 2018-04-06 | 弗洛设计声能学公司 | Sound electrophoretic apparatus with alliteration electrophoresis chamber |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| US12129471B2 (en) | 2015-02-23 | 2024-10-29 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of human genetic diseases including hemoglobinopathies |
| WO2016135558A2 (en) | 2015-02-23 | 2016-09-01 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| EP3763814A1 (en) * | 2015-05-08 | 2021-01-13 | The Children's Medical Center Corporation | Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction |
| CA2986310A1 (en) | 2015-05-11 | 2016-11-17 | Editas Medicine, Inc. | Optimized crispr/cas9 systems and methods for gene editing in stem cells |
| SG10202112057QA (en) | 2015-05-12 | 2021-12-30 | Sangamo Therapeutics Inc | Nuclease-mediated regulation of gene expression |
| US11911415B2 (en) | 2015-06-09 | 2024-02-27 | Editas Medicine, Inc. | CRISPR/Cas-related methods and compositions for improving transplantation |
| WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| EP3371306B8 (en) | 2015-11-04 | 2023-02-22 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of hemoglobinopathies |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| WO2018064387A1 (en) | 2016-09-28 | 2018-04-05 | Novartis Ag | Porous membrane-based macromolecule delivery system |
| KR20240007715A (en) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Aav delivery of nucleobase editors |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| TW201839136A (en) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | Composition and method for treating hemochromatosis |
| KR20190123328A (en) | 2017-03-09 | 2019-10-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Cancer vaccine |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| CN110914310A (en) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | Cytosine to guanine base editor |
| EP3596217A1 (en) | 2017-03-14 | 2020-01-22 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
| IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| EP3606341A4 (en) | 2017-04-04 | 2021-04-21 | The Board of Trustees of the Leland Stanford Junior University | MANUFACTURING, EXPANSION AND USES OF ADULTS PLURIPOTENT STEM CELLS |
| US12110499B2 (en) | 2017-04-24 | 2024-10-08 | Seattle Children's Hospital | Homology directed repair compositions for the treatment of hemoglobinopathies |
| EP3622070A2 (en) * | 2017-05-10 | 2020-03-18 | Editas Medicine, Inc. | Crispr/rna-guided nuclease systems and methods |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| US11788087B2 (en) * | 2017-05-25 | 2023-10-17 | The Children's Medical Center Corporation | BCL11A guide delivery |
| US20200140896A1 (en) | 2017-06-30 | 2020-05-07 | Novartis Ag | Methods for the treatment of disease with gene editing systems |
| EP3652312A1 (en) | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| CA3077391A1 (en) * | 2017-09-29 | 2019-04-04 | Intellia Therapeutics, Inc. | In vitro method of mrna delivery using lipid nanoparticles |
| CN109706148A (en) * | 2017-09-30 | 2019-05-03 | 广东赤萌医疗科技有限公司 | A kind of gRNA, gRNA composition and electric shifting method for knocking out BCL11A gene or BCL11A genetic enhancer |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| MA50849A (en) * | 2017-10-26 | 2020-09-02 | Vertex Pharma | SUBSTANCES AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES |
| CN109722414A (en) * | 2017-10-27 | 2019-05-07 | 博雅辑因(北京)生物科技有限公司 | It is a kind of efficiently to prepare the method for mature erythrocyte and be used to prepare the culture medium of mature erythrocyte |
| EP3704245A1 (en) | 2017-11-01 | 2020-09-09 | Novartis AG | Synthetic rnas and methods of use |
| SG11202004529XA (en) * | 2017-11-16 | 2020-06-29 | Mogam Inst Biomedical Res | Transformed human cell and use thereof |
| WO2019106522A1 (en) * | 2017-11-28 | 2019-06-06 | Novartis Ag | Pooled crispr/cas9 screening in primary cells using guide swap technology |
| JP2021505587A (en) * | 2017-12-05 | 2021-02-18 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | CRISPR-CAS9 modified CD34 + human hematopoietic stem / progenitor cells and their use |
| CN114900773A (en) | 2017-12-14 | 2022-08-12 | 弗洛设计声能学公司 | Acoustophoretic system, method for operating acoustophoretic system, and method for controlling acoustic transducer and acoustic system |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| EP3735412B1 (en) * | 2018-01-03 | 2024-02-21 | EdiGene Biotechnology, Inc. | Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders |
| EP3743516A4 (en) * | 2018-01-26 | 2021-10-13 | The Children's Medical Center Corporation | TARGETING &XC9; L &XC9; MENTS R &XC9; BCL11A DISTAL GULATORS WITH CAS9-CAS9 FUSION FOR R &XC9; INDUCTION OF H &XC9; MOGLOBIN F &X152; TALE |
| MA51787A (en) * | 2018-02-05 | 2020-12-16 | Vertex Pharma | SUBSTANCES AND METHODS OF TREATMENT OF HEMOGLOBINOPATHIES |
| EP3749768A1 (en) * | 2018-02-05 | 2020-12-16 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of hemoglobinopathies |
| IL277234B2 (en) | 2018-03-14 | 2026-03-01 | Editas Medicine Inc | Systems and methods for the treatment of hemoglobinopathies |
| US12522811B2 (en) * | 2018-05-01 | 2026-01-13 | The Children's Medical Center Corporation | Enhanced BCL11A RNP / CRISPR delivery and editing using a 3XNLS-CAS9 |
| US12350284B2 (en) | 2018-05-02 | 2025-07-08 | The Children's Medical Center Corporation | BCL11A microRNAs for treating hemoglobinopathies |
| CN112105732A (en) * | 2018-05-10 | 2020-12-18 | 先正达参股股份有限公司 | Methods and compositions for targeted editing of polynucleotides |
| CN112654710A (en) | 2018-05-16 | 2021-04-13 | 辛瑟高公司 | Methods and systems for directing RNA design and use |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| CA3113255A1 (en) * | 2018-09-21 | 2020-03-26 | APstem Therapeutics, Inc. | Human pluripotent adult stem cells |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| EP3887521A1 (en) * | 2018-11-29 | 2021-10-06 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| WO2020191241A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN111939271A (en) * | 2019-04-30 | 2020-11-17 | 博雅辑因(北京)生物科技有限公司 | Method for predicting treatment effectiveness of hemoglobinopathy |
| CA3138029A1 (en) * | 2019-04-30 | 2020-11-05 | Edigene Inc. | Method for predicting effectiveness of treatment of hemoglobinopathy |
| EP3990650A4 (en) * | 2019-06-28 | 2024-03-20 | ASC Therapeutics Inc. | METHODS AND COMPOSITIONS FOR TREATING THALASSEMIA AND SICKLE CELL ANEMIA |
| CN114364799B (en) * | 2019-08-28 | 2024-07-19 | 甘李药业股份有限公司 | Methods for editing the BCL11A gene in hematopoietic stem/progenitor cells |
| US20220380757A1 (en) * | 2019-09-30 | 2022-12-01 | The Children's Medical Center Corporation | Bcl11a guide and base editor delivery |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| CA3177481A1 (en) | 2020-05-08 | 2021-11-11 | David R. Liu | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| CN114149990A (en) * | 2020-09-08 | 2022-03-08 | 甘李药业股份有限公司 | Method for editing BCL11A gene in hematopoietic stem/progenitor cells |
| US12079386B2 (en) | 2020-09-14 | 2024-09-03 | Zebra Technologies Corporation | Devices having protective screens selectively positionable to switch devices between user interface modes and methods of operating the same |
| EP4255502A4 (en) * | 2020-12-03 | 2025-07-16 | Scribe Therapeutics Inc | COMPOSITIONS AND METHODS FOR TARGETING BCL11A |
| EP4314308A4 (en) * | 2021-04-02 | 2026-05-20 | Univ Shanghai Technology | Gene therapy for the treatment of beta-hemoglobinopathia |
| WO2022240787A1 (en) * | 2021-05-13 | 2022-11-17 | The Children's Medical Center Corporation | Methods for stratifying subjects for fetal hemoglobin reinduction |
| CN113584167B (en) * | 2021-07-07 | 2023-10-03 | 武汉大学中南医院 | A crRNA, isothermal amplification primer and kit for detecting FLT3-F691L mutation |
| EP4273242A1 (en) * | 2022-05-03 | 2023-11-08 | ETH Zurich | Crispr-based modification of human hbd gene |
| WO2023214512A1 (en) | 2022-05-06 | 2023-11-09 | 学校法人常翔学園 | Artificial rna molecule |
| JP2025526403A (en) * | 2022-07-25 | 2025-08-13 | セリントラ・セラピューティクス・エスア | Compositions and methods for genome editing |
| US20240229021A9 (en) * | 2022-10-21 | 2024-07-11 | Georgia Tech Research Corporation | Transcriptional programming in a bacteroides consortium |
| CN116445402B (en) * | 2023-05-09 | 2025-04-25 | 中国科学院生态环境研究中心 | Erythroid progenitor cell expansion culture medium, expansion culture method and application |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025174765A1 (en) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004305111B2 (en) | 2003-12-19 | 2011-04-28 | Novartis Vaccines And Diagnostics, Inc. | Cell transfecting formulations of small interfering RNA, related compositions and methods of making and use |
| PE20100362A1 (en) * | 2008-10-30 | 2010-05-27 | Irm Llc | PURINE DERIVATIVES THAT EXPAND HEMATOPOYETIC STEM CELLS |
| WO2011076807A2 (en) | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| CN103153284B (en) | 2010-07-06 | 2015-11-25 | 诺华股份有限公司 | Liposomes containing lipids whose pKa values are favorable for RNA delivery |
| EP3542789A3 (en) | 2010-08-31 | 2020-01-01 | GlaxoSmithKline Biologicals SA | Lipids suitable for liposomal delivery of protein-coding rna |
| RU2014104090A (en) | 2011-07-06 | 2015-08-20 | Новартис Аг | LIPOSOMES WITH AN EFFECTIVE N: P RATIO FOR DELIVERY OF PHK MOLECULES |
| WO2013059343A1 (en) | 2011-10-17 | 2013-04-25 | Massachusetts Institute Of Technology | Intracellular delivery |
| US9394547B2 (en) | 2012-01-03 | 2016-07-19 | City University Of Hong Kong | Method and apparatus for delivery of molecules to cells |
| US20130178421A1 (en) | 2012-01-06 | 2013-07-11 | Alcon Research, Ltd. | Interfering rna delivery system and uses thereof |
| SI2807165T1 (en) * | 2012-01-27 | 2019-08-30 | Universite De Montreal | Pyrimido (4,5-B) indole derivatives and their use in hematopoietic stem cell expansion |
| EP2836226B1 (en) | 2012-02-24 | 2017-06-28 | Fred Hutchinson Cancer Research Center | Compositions and methods for the treatment of hemoglobinopathies |
| ES2708948T3 (en) * | 2012-11-27 | 2019-04-12 | Childrens Medical Ct Corp | Distal regulatory elements of bcl11a as targets for the reinduction of fetal hemoglobin |
| US8697359B1 (en) * | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| ES2887254T3 (en) | 2013-03-08 | 2021-12-22 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| PL2970948T3 (en) | 2013-03-15 | 2019-06-28 | Glaxosmithkline Biologicals Sa | Rna purification methods |
| CN105408483A (en) * | 2013-03-15 | 2016-03-16 | 通用医疗公司 | RNA-guided targeting of genetic and epigenetic regulatory proteins to specific genomic loci |
| EP2997146A4 (en) * | 2013-05-15 | 2017-04-26 | Sangamo BioSciences, Inc. | Methods and compositions for treatment of a genetic condition |
| WO2014204725A1 (en) * | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation |
| US10124336B2 (en) | 2013-08-16 | 2018-11-13 | Massachusetts Institute Of Technology | Selective delivery of material to cells |
| ES2721936T3 (en) * | 2013-11-13 | 2019-08-06 | Childrens Medical Center | Regulation of nuclease-mediated gene expression |
| US10450586B2 (en) * | 2013-11-28 | 2019-10-22 | Horizon Discovery Limited | Somatic haploid human cell line |
| US10059655B2 (en) | 2013-12-19 | 2018-08-28 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| US10426737B2 (en) | 2013-12-19 | 2019-10-01 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| WO2015148860A1 (en) * | 2014-03-26 | 2015-10-01 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating beta-thalassemia |
| EP3981876A1 (en) * | 2014-03-26 | 2022-04-13 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating sickle cell disease |
| WO2015152305A1 (en) * | 2014-03-31 | 2015-10-08 | 株式会社サイエンス・ラスター | Growth peptide for hematopoietic cells and use for growth peptide for hematopoietic cells |
| WO2015158860A1 (en) * | 2014-04-16 | 2015-10-22 | Sika Technology Ag | Rapid-curing, migration-free composition based on polymers containing silane groups |
| CN106794260B (en) * | 2014-04-25 | 2021-02-23 | 儿童医疗中心有限公司 | Compositions and methods for treating hemoglobinopathies |
| CN104480144B (en) * | 2014-12-12 | 2017-04-12 | 武汉大学 | CRISPR/Cas9 recombinant lentiviral vector for human immunodeficiency virus gene therapy and lentivirus of CRISPR/Cas9 recombinant lentiviral vector |
| EP3763814A1 (en) * | 2015-05-08 | 2021-01-13 | The Children's Medical Center Corporation | Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction |
| CN109706148A (en) * | 2017-09-30 | 2019-05-03 | 广东赤萌医疗科技有限公司 | A kind of gRNA, gRNA composition and electric shifting method for knocking out BCL11A gene or BCL11A genetic enhancer |
| CN109722414A (en) * | 2017-10-27 | 2019-05-07 | 博雅辑因(北京)生物科技有限公司 | It is a kind of efficiently to prepare the method for mature erythrocyte and be used to prepare the culture medium of mature erythrocyte |
| IL277234B2 (en) * | 2018-03-14 | 2026-03-01 | Editas Medicine Inc | Systems and methods for the treatment of hemoglobinopathies |
-
2016
- 2016-12-26 MX MX2018007987A patent/MX2018007987A/en unknown
- 2016-12-26 EP EP16826777.1A patent/EP3397767A1/en not_active Withdrawn
- 2016-12-26 US US16/066,617 patent/US20190010495A1/en not_active Abandoned
- 2016-12-26 CA CA3009727A patent/CA3009727A1/en active Pending
- 2016-12-26 NZ NZ744649A patent/NZ744649A/en unknown
- 2016-12-26 HK HK19100562.7A patent/HK1258205A1/en unknown
- 2016-12-26 IL IL260257A patent/IL260257B2/en unknown
- 2016-12-26 EP EP21213766.5A patent/EP4053277A1/en active Pending
- 2016-12-26 SG SG11201805217XA patent/SG11201805217XA/en unknown
- 2016-12-26 IL IL308706A patent/IL308706A/en unknown
- 2016-12-26 MY MYPI2018001073A patent/MY192848A/en unknown
- 2016-12-26 KR KR1020257030429A patent/KR20250141840A/en active Pending
- 2016-12-26 KR KR1020187021444A patent/KR102860636B1/en active Active
- 2016-12-26 EA EA201891532A patent/EA201891532A1/en unknown
- 2016-12-26 JP JP2018534141A patent/JP2019500043A/en active Pending
- 2016-12-26 NZ NZ783534A patent/NZ783534A/en unknown
- 2016-12-26 CN CN201680082815.6A patent/CN108779462A/en active Pending
- 2016-12-26 AU AU2016381313A patent/AU2016381313B2/en active Active
- 2016-12-26 WO PCT/IB2016/058007 patent/WO2017115268A1/en not_active Ceased
-
2018
- 2018-06-27 MX MX2022009148A patent/MX2022009148A/en unknown
- 2018-06-27 PH PH12018501378A patent/PH12018501378A1/en unknown
-
2020
- 2020-08-27 AU AU2020223733A patent/AU2020223733B2/en active Active
-
2021
- 2021-06-09 JP JP2021096653A patent/JP7851081B2/en active Active
-
2022
- 2022-04-19 AU AU2022202558A patent/AU2022202558A1/en not_active Abandoned
- 2022-10-13 US US17/965,366 patent/US20240002843A1/en active Pending
-
2023
- 2023-08-04 JP JP2023128086A patent/JP7844400B2/en active Active
-
2025
- 2025-01-17 AU AU2025200366A patent/AU2025200366A1/en active Pending
-
2026
- 2026-04-01 JP JP2026060615A patent/JP2026126208A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ783534A (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| EP4545544A3 (en) | Modified crispr rna and modified single crispr rna and uses thereof | |
| PH12018502429A1 (en) | Antibody molecules for cancer treatment | |
| MX2020011939A (en) | Novel crispr enzymes and systems. | |
| SG10201804715WA (en) | Crispr hybrid dna/rna polynucleotides and methods of use | |
| HK1245080A1 (en) | Methods and compositions for natural killer cells | |
| MX2018011114A (en) | Crispr/cas-related methods and compositions for treating beta hemoglobinopathies. | |
| MX2018000147A (en) | Antibody molecules which bind cd45. | |
| MX2018000470A (en) | Antibody molecules which bind cd22. | |
| NZ739133A (en) | Cellular targeted active ingredient delivery system | |
| AU2015311681A8 (en) | Globin gene therapy for treating hemoglobinopathies | |
| MX2023001877A (en) | Engineered meganucleases specific for recognition sequences in the pcsk9 gene. | |
| EP4667565A3 (en) | Methods and compositions for the treatment of fabry disease | |
| MX2017011997A (en) | Piperazine carbamates and methods of making and using same. | |
| MA40460A (en) | Lysosomal targeting and uses thereof | |
| MY194603A (en) | Anti-Complement Factor Bb Antibodies And Uses Thereof | |
| EP4663247A3 (en) | Formulations/compositions comprising a btk inhibitor | |
| WO2015168521A3 (en) | P97-polynucleotide conjugates | |
| MX2019002960A (en) | Modified oligonucleotides and methods of use. | |
| WO2018183692A8 (en) | Vectors and compositions for treating hemoglobinopathies | |
| ZA201803476B (en) | Anti-cd22 antibody-maytansine conjugates and methods of use thereof | |
| MX2020013732A (en) | Methods of manufacturing amino acid compositions. | |
| MX2017008390A (en) | Alkoxysilane-functionalized and allophanate-functionalized urethanes. | |
| MX373409B (en) | COMPOSITIONS FOR KERATIN FIBERS. | |
| MX2019006551A (en) | Gene therapy for mucopolysaccharidosis, type ii. |